Caricamento...
Castrate Resistant Prostate Cancer: Post-Docetaxel Management
PURPOSE OF REVIEW: Prior to 2010, docetaxel was the only treatment shown to prolong survival in metastatic castrate resistant prostate cancer (CRPC). In the past three years several therapeutic agents have demonstrated survival improvements for CRPC after receipt of prior docetaxel, leading to multi...
Salvato in:
| Pubblicato in: | Curr Opin Urol |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4486479/ https://ncbi.nlm.nih.gov/pubmed/23344012 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOU.0b013e32835e2253 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|